Edition:
India

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

16.40USD
19 Jan 2018
Change (% chg)

$1.25 (+8.25%)
Prev Close
$15.15
Open
$15.20
Day's High
$17.35
Day's Low
$14.90
Volume
641,277
Avg. Vol
237,769
52-wk High
$19.90
52-wk Low
$11.85

Chart for

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20... (more)

Overall

Beta: 1.76
Market Cap(Mil.): $987.19
Shares Outstanding(Mil.): 76.23
Dividend: --
Yield (%): --

Financials

BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However

* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:

08 Jan 2018

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

05 Jan 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

04 Jan 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

04 Jan 2018

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Jan 3 Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

04 Jan 2018

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

04 Jan 2018

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

01 Nov 2017

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

01 Nov 2017

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

02 Aug 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

24 Jul 2017

Competitors

Earnings vs. Estimates